330 likes | 679 Views
Sindrome di POEMS. Orvieto, 20-22 Novembre 2009 Rita Emili S.C. Oncoematologia, A.O. S. Maria, Terni Università degli Studi di Perugia. Definizione. P olyneuropathy O rganomegaly E ndocrinopaty M onoclonal plasma cell disorder S kin changes. Dispenzieri, Blood, 2003. Epidemiologia.
E N D
Sindrome di POEMS Orvieto, 20-22 Novembre 2009 Rita Emili S.C. Oncoematologia, A.O. S. Maria, Terni Università degli Studi di Perugia
Definizione • Polyneuropathy • Organomegaly • Endocrinopaty • Monoclonalplasma cell disorder • Skinchanges Dispenzieri, Blood, 2003
Epidemiologia • Età media : 50/60 anni • Popolazione colpita : Giapponesi, Europei, Africani, Ispanici, Asiatici Dispenzieri, Orphanet Enc., 2005
Patogenesi sconosciute • CAUSE : Aumento del livello delle citochine: VEGF, IL-1β, TNF-α, IL-6 RK Gherardi, Blood, 1994
IL-1β in POEMS syndrome (A) Angiofollicular lymph node hyperplasia with atrophic germinal centers (arrowheads) and sinusal histicytosis (stars) (B) In situ hybridization performed with IL-p sense probe used as control showing no signal (C) In situ hybridization performed with IL-p anti-sense probe showing abundant radiolabeledI L-1p mRNA-producing cells scatteredin the interfollicular spaces (D) In the other studied patient, radiolabeledI L-1p mRNA-producing cellsw ere similarly distributed in the interfollicular spaces RK Gherardi, Blood, 1994
Criteri di diagnosi • Major criteria (both) • Polyneuropathy • Monoclonal plasma cell-proliferative disorder Dispenzieri, Blood, 2003
Criteri di diagnosi • Organomegaly • Edema • Endocrinopathy • Skin changes • Sclerotic bone lesions • Papilledema • Castleman disease • Minor criteria (plus at least one) Dispenzieri, Blood, 2003
Criteri di diagnosi • Known associations • Weight loss • Thrombocytosis • Polycythemia • Hyperhidrosis • Clubbing Dispenzieri, Blood, 2003
Criteri di diagnosi • Possible associations • Restrictive lung disease • Thrombotic diatheses • Arthralgias • Cardiomyopathy (systolic dysfunction) • Fever • Low vitamin B12 values • Diarrhea • Pulmonary hypertension Dispenzieri, Blood, 2003
Caratteristiche cliniche alla diagnosi Clinical features present at diagnosis in 99 patients with POEMS seen at the Mayo Clinic from 1975 to 1998 Dispenzieri, Blood, 2003
Caratteristiche cliniche alla diagnosi Ns – not stated Dispenzieri, Blood, 2003
Polyneuropathy • Cerebrospinal fluid protein more than 50 mg/dlt • Peripheral neuropathy: Distal, symmetric, progressive • paresthesias • coolness • tingling • Motor involvement follows the sensory syntoms. Dispenzieri, Blood, 2003
Organomegaly • Hepatomegaly • Splenomegaly • Lymphadenopaty(between 11%-30% Castelman disease presents) Dispenzieri, Blood, 2003
Endocrinopathy • Diabetes mellitus • Hypothyroidism • Hyperparathyroidism • Gonadal axis abnormality • Adrenal axis abnormality Dispenzieri, Blood, 2003
Monoclonal plasma proliferative disorder • Serum M-spike (gm/dL) : usually < 2 • Monoclonal heavy chain : IgG > IgA > IgM • Monoclonal light chain : Lambda > 95% • BM plasma cells % : usually < 5 Dispenzieri, Blood, 2003
Skin changes • Hyperpigmentation • Acrocyanosis and plethora • Hemangioma/telangectasia • Hypetrichosis • Thickening Dispenzieri, Blood, 2003
Other features 1 • Sclerotic bones lesions • mixed sclerotic and lytic • osteosclerotic only • lytic only • > 1 lesion • Extravascular volume overload • Peripheral edema • Ascites • Pleural effusion Dispenzieri, Blood, 2003
Other features 2 • Papilledema • Trombocytosis • Polycythemia • Clubbing • Weight loss more 10 pounds • Fatigue Dispenzieri, Blood, 2003
Overall survival A. Overall survival in 99 patients receiving conventional dose chemotherapy. B. After peripheral blood stem cell transplant. Dispenzieri, Hematology, 2005
Overall survival Dispenzieri, Blood, 2003
Trattamento Dispenzieri, Blood, 2003
Trattamento • Radioterapia : singole o multiple lesioni osteosclerotiche in una limitata area Dispenzieri, Blood, 2003
Trattamento • Terapia sistemica : diffuse lesioni osteosclerotiche • Agenti alchilanti • Corticosteroidi • Chemioterapia ad alte dosi con trapianto di cellule staminali • Talidomide • Lenalidomide • Bortezomib Dispenzieri, Blood, 2003
Trattamento Nuovi Agenti • Talidomide • Lenalidomide • Bortezomib ? ? ? ? ? ? Dispenzieri, Blood, 2003
Trattamento • Talidomide: 200mg/die-300mg/die • Anti VEGF • Anti TNF • Immunomodulatore Dispenzieri, Blood, 2003
Trattamento • Lenalidomide: 15-25 mg/die x 21 giorni (in associazione a desametasone) • Anti VEGF • Anti TNF • Immunomodulatore Dispenzieri, Blood, 2003
Trattamento • Bortezomib: 1,3-1,6 mg/mq • Inibitore del proteosoma • Inibitore di citochineproinfiammatorie e proangiogeniche Dispenzieri, Blood, 2003
High -dose chemotherapy with hematopoietic stem cell transplantation 1 Dispenzieri, Blood, 2003
High -dose chemotherapy with hematopoietic stem cell transplantation 2 Dispenzieri, Blood, 2003
Conclusioni • Diagnosi – presenza di due criteri maggiori e almeno uno minore • Diagnosi differenziale – mieloma multiplo, malattia di Waldenström, crioglobulinemia, amiloidosi primaria • Terapia – radioterapia e chemioterapia • Sopravvivenza – migliore rispetto ai pazienti con mieloma multiplo. Dispenzieri, Blood, 2003